Leal Health
Leal Health is a patient-first digital health company focused on democratizing access to advanced cancer treatment through an AI-powered decision support platform. The company has successfully made over 4.5 million treatment matches for patients, partnering with leading advocacy and patient support organizations to ensure unbiased access to cancer treatment. Recognized for its innovative approach, Leal Health empowers patients to take control of their cancer journey by providing personalized treatment options and support from a dedicated team of healthcare professionals. With a strong market position and recognition from industry awards, Leal is at the forefront of transforming cancer care.
Leal Health
Leal Health is a patient-first digital health company focused on democratizing access to advanced cancer treatment through an AI-powered decision support platform. The company has successfully made over 4.5 million treatment matches for patients, partnering with leading advocacy and patient support organizations to ensure unbiased access to cancer treatment. Recognized for its innovative approach, Leal Health empowers patients to take control of their cancer journey by providing personalized treatment options and support from a dedicated team of healthcare professionals. With a strong market position and recognition from industry awards, Leal is at the forefront of transforming cancer care.
TL;DR
What they do: AI-powered patient-facing platform for cancer treatment and clinical trial matching
Scale: Platform reports millions of treatment matches (site cites 3M–4.5M)
Founded / HQ: Launched Dec 2017; headquartered in New York
Team size: Approximately 11–50 employees (source snapshots list 27)
Funding: Has raised multiple rounds including a Series A (Feb 7, 2022); total disclosed funding ~$27.72M
Company Overview
Problem Domain
Oncology care access; clinical trial matching; treatment decision support
Founded
2017
Industry
Digital health; oncology
Funding Track Record
Series A announced Feb 7, 2022
Public profiles indicate pre-seed (Jul 2018), seed (Dec 2019) and a Feb 2021 round
Dealroom lists an April 2024 Series B entry (reported $26.0M by that source)
Investor Signal
“Insight Partners, TIA Ventures, Rho Ventures, JAL Ventures, Contour Venture Partners, Connecticut Innovations”